` ABEO (Abeona Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

ABEO
vs
S&P 500

Over the past 12 months, ABEO has underperformed S&P 500, delivering a return of -10% compared to the S&P 500's +14% growth.

Stocks Performance
ABEO vs S&P 500

Loading
ABEO
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ABEO vs S&P 500

Loading
ABEO
S&P 500
Difference
www.alphaspread.com

Performance By Year
ABEO vs S&P 500

Loading
ABEO
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Abeona Therapeutics Inc vs Peers

S&P 500
ABEO
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Abeona Therapeutics Inc
Glance View

Market Cap
267.8m USD
Industry
Biotechnology

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. The company is headquartered in New York City, New York and currently employs 90 full-time employees. The Company’s lead clinical programs consist of EB-101, which is an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102, which is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101, which is an AAV-based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company is focused on to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM capsid platform that has a license from the University of North Carolina at Chapel Hill and internal AAV vector research programs.

ABEO Intrinsic Value
50.12 USD
Undervaluation 90%
Intrinsic Value
Price
Back to Top